Regenerate, Inc.

CLOSTER, NJ · Founded 2010 · CIK 0001504966 · Biotech · Public

Proprietary technology to safely lengthen telomeres in human cells

rejuvenationtech.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$2.3M
1 Form D · Nov 2010
191 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$2,300,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2543Trekka Therapeutics, LLC——
2544Rare Air Health, Inc.—$4.7M
2545Neela Therapeutics, Inc.—$12M
2546Regenerate, Inc.—$2.3M
2547ANAGIN—$2.3M
2548Amplo Biotechnology, Inc.—$2.2M
2549Mira Dx, Inc.—$2.1M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • Susan FuExecutive Officer
  • Jeremy MaoDirector
  • Hong ZhanDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.